Financial Performance - The group's revenue for the nine months ended December 31, 2022, was approximately HKD 56,000,000, a decrease of 29.3% compared to HKD 79,300,000 for the same period in 2021[6] - The loss attributable to owners of the company for the nine months ended December 31, 2022, was approximately HKD 34,400,000, compared to a loss of HKD 29,700,000 for the same period in 2021, representing a 15.4% increase in losses[6] - For the three months ended December 31, 2022, the group's revenue was HKD 14,017,000, down 47.1% from HKD 26,414,000 in the same quarter of 2021[7] - The gross profit for the nine months ended December 31, 2022, was HKD 29,590,000, a decrease of 27.3% from HKD 40,704,000 for the same period in 2021[7] - Operating loss for the nine months ended December 31, 2022, was HKD 32,367,000, compared to HKD 29,783,000 for the same period in 2021, indicating a 8.7% increase in operating losses[7] - The total comprehensive loss for the nine months ended December 31, 2022, was HKD 34,439,000, compared to HKD 29,748,000 for the same period in 2021[8] - The company reported a basic and diluted loss per share of HKD 10.89 cents for the nine months ended December 31, 2022, compared to HKD 10.87 cents for the same period in 2021[7] - The company reported a loss per share of approximately HKD 0.087 for the nine months ended December 31, 2022, compared to HKD 0.109 for the same period in 2021[21] Dividend Policy - The board of directors did not recommend the payment of dividends for the nine months ended December 31, 2022, consistent with the previous year[6] - The company did not recommend the payment of dividends for the nine months ended December 31, 2022, consistent with the previous year[19] Revenue Breakdown - Revenue from lending for the three months ended December 31, 2022, was HKD 3,398,000, while for the nine months it was HKD 19,650,000, down from HKD 25,828,000 in the previous year[14] - Revenue from retail and wholesale sales of grocery products, cash vouchers, and frozen foods for the three months ended December 31, 2022, was HKD 10,619,000, compared to HKD 17,621,000 in the same period of 2021[14] - The company’s income from external customers in Hong Kong for the nine months ended December 31, 2022, was HKD 56,030,000, down from HKD 79,256,000 in the previous year[16] - Lending division generated approximately HKD 19,700,000 in revenue over the nine-month period, with expectations for continued stable income in the future[28] - Retail and wholesale business revenue decreased by about 32% compared to the same period in 2021, totaling approximately HKD 36,400,000, down from HKD 53,400,000[30] Product Development - The company has launched a new product line for pet products, including supplements and pet food, as part of its strategy to meet changing customer demands[26] - The company continues to develop its own brand products to adapt to market changes, including a new line of human health supplements named "Cordyceps 19" due to the COVID-19 pandemic[26] - The company launched new product lines in pet products and human supplements, leading to a significant increase in inventory and deposits as of December 31, 2022[31] Capital and Shareholder Information - The company completed a share placement on November 21, 2022, issuing 72,105,000 shares at a placement price of HKD 0.149 per share, raising approximately HKD 10,744,000[33] - The net proceeds from the placement, estimated at HKD 9,819,000, will be used for expanding the lending business and general working capital[33] - The company agreed to acquire approximately 90.1% of the shares in Lianwang Limited for HKD 1,000,000, along with a subscription agreement for 43,000,000 new shares at HKD 0.20 each[35] - A similar acquisition was made for approximately 90.1% of Pet Supermarket Limited, with the same terms as the previous acquisition[36] - The company’s capital structure changed with the number of issued shares increasing from 360,539,031 to 432,644,031 after the placement[34] - As of December 31, 2022, the major shareholder, Baofeng Management Limited, held approximately 41.88% of the issued share capital[39] Corporate Governance - The company has adopted the trading standards as per GEM Listing Rules 5.48 to 5.67, confirming compliance by all directors during the nine-month period[42] - The company has adhered to the corporate governance code as outlined in Appendix 15 of the GEM Listing Rules throughout the nine-month period[43] - An audit committee has been established to review the annual report, financial statements, interim reports, and quarterly reports, ensuring compliance with applicable accounting standards[44] - The unaudited consolidated performance for the nine-month period has been reviewed by the audit committee, which confirmed that the performance was prepared in accordance with applicable accounting standards and regulations[46] - A remuneration committee has been formed, consisting of four independent non-executive directors and three executive directors, to review and establish remuneration policies based on operational performance and market practices[47] - A nomination committee has been established to review any proposed changes and recommend candidates for directorships to the board[48] - The board of directors includes four executive directors and four independent non-executive directors, ensuring a balanced governance structure[49]
仍志集团控股(08079) - 2023 Q3 - 季度财报